From GlobeNewswire: 2025-06-11 11:30:00

Onconetix, Inc. announces stockholders’ approval of a 1-for-85 reverse stock split effective June 13, 2025. The split aims to regain compliance with Nasdaq’s $1.00 per share bid price requirement for continued listing. No fractional shares will be issued, and ownership percentages will remain unchanged. The split will reduce outstanding shares from 44.4 million to approximately 521,863. Onconetix focuses on men’s health and oncology, owning Proclarix and ENTADFI for prostate cancer and benign prostatic hyperplasia treatment, respectively. Forward-looking statements caution investors about risks related to commercialization and regulatory approval. Contact Onconetix for more information.



Read more at GlobeNewswire: Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and